LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MCF 10A | GSK1059615 | 1.11 | uM | LJP6 | 3 | C03 | 72 | hr | 962 | 1845 | 10641 | 0.1734 | 0.2066 |
MCF 10A | GSK1059615 | 1.11 | uM | LJP5 | 1 | E03 | 72 | hr | 962 | 1311 | 10714 | 0.1224 | 0.0931 |
MCF 10A | GSK1059615 | 1.11 | uM | LJP5 | 2 | E03 | 72 | hr | 962 | 1412 | 10507 | 0.1344 | 0.1176 |
MCF 10A | GSK1059615 | 1.11 | uM | LJP5 | 3 | E03 | 72 | hr | 962 | 1562 | 10315 | 0.1514 | 0.1521 |
MCF 10A | GSK1059615 | 3.33 | uM | LJP6 | 1 | C02 | 72 | hr | 962 | 621 | 10693 | 0.0581 | -0.1184 |
MCF 10A | GSK1059615 | 3.33 | uM | LJP6 | 2 | C02 | 72 | hr | 962 | 769 | 10740 | 0.0716 | -0.0624 |
MCF 10A | GSK1059615 | 3.33 | uM | LJP6 | 3 | C02 | 72 | hr | 962 | 845 | 10641 | 0.0794 | -0.0368 |
MCF 10A | GSK1059615 | 3.33 | uM | LJP5 | 1 | E02 | 72 | hr | 962 | 696 | 10714 | 0.0650 | -0.0889 |
MCF 10A | GSK1059615 | 3.33 | uM | LJP5 | 2 | E02 | 72 | hr | 962 | 801 | 10507 | 0.0762 | -0.0518 |
MCF 10A | GSK1059615 | 3.33 | uM | LJP5 | 3 | E02 | 72 | hr | 962 | 921 | 10315 | 0.0893 | -0.0127 |
MCF 10A | GSK1059615 | 10 | uM | LJP6 | 1 | C01 | 72 | hr | 962 | 429 | 10693 | 0.0401 | -0.2074 |
MCF 10A | GSK1059615 | 10 | uM | LJP6 | 2 | C01 | 72 | hr | 962 | 521 | 10740 | 0.0485 | -0.1616 |
MCF 10A | GSK1059615 | 10 | uM | LJP6 | 3 | C01 | 72 | hr | 962 | 525 | 10641 | 0.0493 | -0.1603 |
MCF 10A | GSK1059615 | 10 | uM | LJP5 | 1 | E01 | 72 | hr | 962 | 454 | 10714 | 0.0424 | -0.1943 |
MCF 10A | GSK1059615 | 10 | uM | LJP5 | 2 | E01 | 72 | hr | 962 | 465 | 10507 | 0.0443 | -0.1901 |
MCF 10A | GSK1059615 | 10 | uM | LJP5 | 3 | E01 | 72 | hr | 962 | 521 | 10315 | 0.0505 | -0.1641 |
MCF 10A | Brivanib | 0.04 | uM | LJP5 | 1 | P18 | 72 | hr | 962 | 10632 | 10714 | 0.9924 | 0.9956 |
MCF 10A | Brivanib | 0.04 | uM | LJP5 | 2 | P18 | 72 | hr | 962 | 10454 | 10507 | 0.9949 | 0.9970 |
MCF 10A | Brivanib | 0.04 | uM | LJP5 | 3 | P18 | 72 | hr | 962 | 10559 | 10315 | 1.0236 | 1.0137 |
MCF 10A | Brivanib | 0.12 | uM | LJP5 | 1 | P17 | 72 | hr | 962 | 10457 | 10714 | 0.9760 | 0.9861 |
MCF 10A | Brivanib | 0.12 | uM | LJP5 | 2 | P17 | 72 | hr | 962 | 10461 | 10507 | 0.9955 | 0.9974 |
MCF 10A | Brivanib | 0.12 | uM | LJP5 | 3 | P17 | 72 | hr | 962 | 10601 | 10315 | 1.0277 | 1.0160 |
MCF 10A | Brivanib | 0.37 | uM | LJP5 | 1 | P16 | 72 | hr | 962 | 10105 | 10714 | 0.9432 | 0.9666 |
MCF 10A | Brivanib | 0.37 | uM | LJP5 | 2 | P16 | 72 | hr | 962 | 9964 | 10507 | 0.9482 | 0.9694 |
MCF 10A | Brivanib | 0.37 | uM | LJP5 | 3 | P16 | 72 | hr | 962 | 10266 | 10315 | 0.9952 | 0.9972 |